Oryzon Wins Spanish Authorization for Iadademstat Trial in High-Risk AML
Oryzon obtained authorization in Spain for an iadademstat trial in high-risk acute myeloid leukemia.
Related stories
Waters Acquires Mobilion Systems
Waters said it acquired Mobilion Systems, adding ion-mobility separation technology to its mass spectrometry portfolio.
M impact | EQUITY | Nov 03, 2026, 10:56 AM UTC
Kia America October Sales Rise 16%
Kia America said it achieved record overall and retail sales for a sixth consecutive month, driven by demand for electrified vehicles and hybrids. It sold 80,008 vehicles.
M impact | EQUITY | Nov 03, 2026, 10:54 AM UTC
Advanced Info Service Reports Quarterly Revenue of 58.06 Billion Baht
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Cosmo First Q2 Consolidated Revenue From Operations INR 13,878.6 Million
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Cosmo First Reports Q2 Consolidated Net Profit of INR 985.8 Million
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Advanced Info Service Reports Quarterly Profit of 13.50 Billion Baht
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC